Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Amgen Inc. (AMGN) Presents at Citi 15th Annual Biopharma Conference (Transcript)

Amgen has an impressive portfolio of assets. It has seen revenue increase through COVID-19 increasing 6% YoY.

Amgen: Massive Pharmaceutical Strength

Chevron

Discovery

Home Depot

Lennar

Simon Property Group

Target

We hear numerous market strategists talk about stocks which are going up because "there is no alternative" to owning them.

There Is No Alternative

Amgen Still A Buy After Joining The Dow

THOUSAND OAKS, Calif., Sept. 4, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 15th Annual Virtual BioPharma Conference at 2:25 p.m.

Amgen To Present At The 15th Annual Citi BioPharma Conference

Gilead Sciences

Moderna

Sanofi

The United States is ensuring adequate doses of the Coronavirus vaccine once it is developed. Some companies leading the race are Moderna, Inc.

Vaccine Hopes Rise Again: 4 Stocks to Watch

AstraZeneca

SPDR Dow Jones Industrial Average ETF

Invesco Dow Jones Industrial Average Dividend ETF

Dow Inc

Coca-Cola

Merck

The Dow jumped above 29,000 for the first time since February on Sep 2 on low rates and vaccine hopes.

Dow Jones Tops 29,000: Will ETFs & Stocks Rally in September?

Amgen (AMGN) stock has posted strong returns in the past five years but has now reached long-term resistance.

Is Amgen (AMGN) a Good Choice for Dow Membership?

Ameriprise Financial

Best Buy

Blackrock Inc

Clorox

Comcast

Garmin

Infosys

KLA-Tencor

Southwest Airlines

State Street

Taiwan Semiconductor Manufacturing

Releasing two top mega-cap stocks from the MDA Growth and Dividend Breakout portfolio for long-term gain potential into 2020.

V&M Breakouts: Top Growth And Dividend Mega-Cap Stocks For September 2020

Cogent Communications Holdings

Exelon

Huntington Ingalls Industries

Iron Mountain

Pfizer

The stock market is heating up faster than we had imagined. Some of our positions are approaching "Sell" territory.

Back To School: 8 Hot All Weather Dividend Buys, And 3 We Might Sell

Salesforce

Honeywell

Raytheon Technologies

Exxon Mobil

The Dow Jones is a rare example of an index constructed on the basis of a component's share price.

Lessons for Equity Investors From Dow Jones' Big Shake-Up

Walmart

Dow Jones Slumps 200 Points as Index Changes Take Effect, Walmart Stock Downgraded

Whether Dumped By The Dow Or Added To It, Companies Should Be Judged On Their Own Merits

Apple

The revamp is likely to make the Dow more market-friendly and reflect investors' sentiments more accurately.

Dow Turns Green YTD in Old Format: What Will the Revamp Unfold?

THOUSAND OAKS, Calif., Aug. 29, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive data from the HAUSER-RCT Phase 3b study evaluating the safety and efficacy of Repatha® (evolocumab) in pediatric patients, 10-17 years of age, with heterozygous familial hypercholesterolemia.

Amgen Announces Positive Data From Phase 3B Study Of Repatha® (Evolocumab) In Pediatric Patients With Heterozygous Familial Hypercholesterolemia At ESC Congress 2020

Biogen

Incyte

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

Biotech Industry Near-Term Outlook Modest Amid Coronavirus

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock?

Why Is Amgen (AMGN) Up 0.5% Since Last Earnings Report?

Discover what's causing the biggest change in Dow components since 2013.

Dow Shake-Up Explained

A Relative Strength Rating upgrade for Amgen shows improving technical performance. Will it continue?

Stock Upgrades: Amgen Shows Rising Relative Strength

Of the three newest names joining the Dow, the options market is betting Amgen might be the biggest winner.

Amgen could be the biggest winner of the Dow shake-up, says the options market

The short interest data are out for August 14, the most recent settlement date. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside.

Major Biotechs Scare Off Short Sellers

Find out what the three new members mean for investors.

Here's What's Happening to the Dow's 27 Other Stocks

The iconic index is getting an adjustment to better reflect the U.S. economy.

Salesforce, Amgen, and Honeywell Are Being Added to the Dow Jones Index: Are They Buys?

"This rebalancing came about because of a need for more technology in this index," the "Mad Money" host said.

Cramer reacts to Dow Jones additions of Salesforce, Amgen and Honeywell: 'The job's almost done'

Big changes to the Dow Jones Industrials index had a market-moving impact on the S&P 500 today.

News for Amgen Stock (AMGN)